QLS-215 is a monoclonal antibody commercialized by Astria Therapeutics, with a leading Phase II program in Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency). According to Globaldata, it is involved in 3 clinical trials, of which 2 are ongoing, and 1 is planned. GlobalData uses proprietary data and analytics to provide a complete picture of QLS-215’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

The revenue for QLS-215 is expected to reach an annual total of $389 mn by 2038 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

QLS-215 Overview

STAR-0215 is under development for the treatment of hereditary angioedema. The drug candidate acts by targeting plasma kallikrein. It is administered through subcutaneous route.

Astria Therapeutics Overview

Astria Therapeutics (Astria), formerly Catabasis Pharmaceuticals, is a clinical-stage biopharmaceutical company. The company discovers, develops and commercializes medicines for the treatment of multiple diseases. It develops its product candidates using its proprietary safely metabolized and rationally targeted (SMART) Linker drug discovery platform for rare diseases, among others. Astria product candidate edasalonexent CAT-1004, currently under Phase 3 trial, is an oral small molecule intended for the treatment of Duchenne muscular dystrophy. CAT-5571, an activator of autophagy and the company’s lead product under preclinical stage, is an oral small molecule for the treatment of cystic fibrosis. The company’s CAT-4001 is used for the treatment of neurodegenerative diseases such as Friedreich’s ataxia and amyotrophic lateral sclerosis (ALS). Astria is headquartered in Cambridge, Massachusetts, the US

The operating loss of the company was US$195 million in FY2021, compared to an operating loss of US$37.4 million in FY2020. The net loss of the company was US$194.9 million in FY2021, compared to a net loss of US$37.3 million in FY2020.

For a complete picture of QLS-215’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.